LENZ Therapeutics (LENZ) Common Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Common Equity data on file, last reported at $246.5 million in Q1 2026.

• Quarterly Common Equity rose 28.37% year-over-year to $246.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $246.5 million (up 28.37% YoY) and the FY2025 annual result came in at $284.3 million, up 39.32% from the prior year.
• Common Equity eased to $246.5 million in Q1 2026 per LENZ's latest filing, from $284.3 million in the prior quarter.
• Across five years, Common Equity topped out at $361.3 million in Q1 2022 and bottomed at -$92.7 million in Q4 2023.
• The 5-year median for Common Equity is $198.2 million (2024), against an average of $157.4 million.
• The widest annual swing landed in 2023, when Common Equity slumped 283.6%; it then jumped 640.29% in 2024.
• Tracing LENZ's Common Equity over 5 years: stood at -$24.2 million in 2022, then tumbled by 283.6% to -$92.7 million in 2023, then soared by 320.13% to $204.1 million in 2024, then surged by 39.32% to $284.3 million in 2025, then declined by 13.31% to $246.5 million in 2026.
• Per Business Quant, the three latest LENZ Common Equity figures stand at $246.5 million (Q1 2026), $284.3 million (Q4 2025), and $193.9 million (Q3 2025).

Peer Comparison